10-K: TherapeuticsMD Reports 2024 Results, Navigates Going Concern Uncertainty

TherapeuticsMD, now a royalty-focused company, faces going concern doubts despite revenue increase and cost reductions following its strategic shift in 2022.

Summary

• TherapeuticsMD transitioned to a pharmaceutical royalty company in December 2022, licensing its women's healthcare products.
• The company's primary revenue source is royalties from licensed products, mainly through the Mayne License Agreement.
• Revenue increased by 35.3% to $1.76 million in 2024, driven by changes in sales of licensed products.
• The company experienced a net loss of $2.2 million in 2024, compared to a net loss of $10.3 million in 2023.
• Operating expenses decreased by 33.6% to $6.5 million in 2024 due to cost optimization.
• There is substantial doubt about the company's ability to continue as a going concern, influenced by factors like Mayne Pharma's sales performance and potential working capital adjustments.
• The company is pursuing equity and debt financing alternatives to address liquidity needs.
• As of December 31, 2024, the company had cash and cash equivalents of $5.1 million.
• The company is involved in ongoing disputes with Mayne Pharma regarding net working capital allowances.
• The company is dependent on third parties achieving specified milestones and product sales.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While revenue increased and operating expenses decreased, the company faces significant challenges, including doubts about its ability to continue as a going concern and ongoing disputes with Mayne Pharma. The overall sentiment is cautiously negative.

Positives

• License revenue increased by 35.3% to $1.76 million in 2024.
• Operating expenses decreased by 33.6% to $6.5 million in 2024.
• Net loss decreased from $10.3 million in 2023 to $2.2 million in 2024.
• The company received a one-time payment of $1.25 million from its sublessee on its early termination on the sublease.

Negatives

• There is substantial doubt about the company's ability to continue as a going concern.
• The company is involved in ongoing disputes with Mayne Pharma regarding net working capital allowances.
• The company recognized an impairment loss of $1.3 million related to abandoned patents and applications.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional capital and minimizing operational expenses.
• The company's revenue is dependent on the sales performance of its licensees.
• The company is involved in ongoing disputes with Mayne Pharma regarding net working capital allowances, which could adversely affect its financial position.
• The company's existing cash reserves may be insufficient to satisfy its liquidity requirements.
• The announcement and pendency of Mayne Pharma Groups agreement to be acquired by Cosette Pharmaceuticals, Inc. could have an adverse effect on our business, operations, and financial condition.

Future Outlook

The company's future performance is dependent on the sales performance of its licensees and its ability to secure additional financing. The company is pursuing equity and debt financing alternatives to address liquidity needs.

Industry Context

The company operates in the pharmaceutical industry, which is characterized by intense competition, government regulation, and the need for continuous innovation. The company's transition to a royalty-focused model reflects a strategic shift to reduce operating expenses and focus on leveraging its intellectual property.

Comparison to Industry Standards

• It is difficult to compare TherapeuticsMD directly to industry standards due to its unique royalty-focused business model after divesting its commercial operations.
• Comparable royalty-based pharmaceutical companies include Ligand Pharmaceuticals and Royalty Pharma, which focus on acquiring royalty streams from marketed drugs and late-stage development products.
• These companies typically have high gross margins but also face risks related to the performance of the underlying products and the potential for generic competition.
• TherapeuticsMD's success will depend on its ability to manage its expenses and generate sufficient royalty revenue to offset its liabilities and achieve profitability.

Legal Proceedings

• The company is involved in ongoing patent infringement litigation with Teva Pharmaceuticals USA, Inc. regarding its IMVEXXY product.
• The company is involved in ongoing patent infringement litigation with Sun Pharma Inc. regarding its IMVEXXY product.

Related Party Transactions

• Mr. Justin Roberts, a director of the company, is a Partner of Rubric Capital Management LP.
• The company has entered into subscription agreements with Rubric Capital Management LP.
• On December 30, 2022, the company redeemed all 29,000 outstanding shares of Series A Preferred Stock previously issued to affiliates of Rubric at a purchase price of $1,333 per share.
• The company also paid certain affiliates of Rubric approximately $3.0 million as a make-whole payment pursuant to the subscription agreements previously entered into between the company and Rubric.

Stakeholder Impact

• Shareholders may experience dilution upon future equity issuances.
• The company's ability to continue as a going concern is uncertain, which could impact the value of shareholders' investments.
• The company's employees are limited to one full-time employee.
• The company's customers are now served by its licensees, such as Mayne Pharma, Theramex and Knight.
• The company's suppliers are now primarily serving its licensees.

Next Steps

• The company intends to resolve the ongoing disputes with Mayne Pharma regarding net working capital allowances.
• The company may pursue various equity and debt financing and other alternatives to address its liquidity needs.

Key Dates

Keywords

TherapeuticsMD, royalties, Mayne Pharma, license agreement, going concern, financial results, IMVEXXY, BIJUVA, ANNOVERA, revenue